See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Merck & Co., Inc. (MRK) - free report >>
Novavax, Inc. (NVAX) - free report >>
Virtus LifeSci Biotech Clinical Trials ETF (BBC) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck & Co., Inc. (MRK) - free report >>
Novavax, Inc. (NVAX) - free report >>
Virtus LifeSci Biotech Clinical Trials ETF (BBC) - free report >>
Image: Bigstock
Biotech ETF (BBC) Hits a New 52-Week High
For investors seeking momentum, Virtus LifeSci Biotech Clinical Trials ETF (BBC - Free Report) is probably on radar. The fund just hit a 52-week high, and is up about 84% from its 52-week low price of $22.92/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:
BBC in Focus
BBC focuses on the biotechnology segment of the U.S. market with equal-weight exposure across stocks. It invests in biotechnology companies with a primary product offering that is in a phase 1, phase 2 or phase 3 clinical-trial stage of development. The fund charges investors 79 basis points a year in fees (see: all the Healthcare ETFs here).
Why the Move?
The biotech corner of the broad healthcare sector has been an area to watch lately, given the positive developments in coronavirus treatment. Novavax (NVAX - Free Report) is the latest drugmaker to start the phase 1 clinical trial of the coronavirus vaccine candidate called NVX-CoV2373 and has enrolled the trial’s first participants, with preliminary results expected in July. Merck (MRK - Free Report) also joined the COVID-19 race with the potential development of two vaccines and one antiviral treatment.
More Gains Ahead?
Currently, BBC has a Zacks ETF Rank #3 (Hold) with a High risk outlook. Therefore, it is hard to get a handle on its future returns one way or the other. However, many of the segments that make up this ETF have a strong Zacks Industry Rank. So, there is definitely some promise for those who want to ride this surging ETF a little further.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>